Difference between revisions of "Rasburicase (Elitek)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*7/12/2002: [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080525.htm FDA approved] "for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid."<ref name="insert"></ref> | *7/12/2002: [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080525.htm FDA approved] "for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid."<ref name="insert"></ref> | ||
| − | + | ==History of changes in EMA indication== | |
| + | *2/23/2001: Initial authorization as Fasturtec | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Elitek, Fasturtec, Rasbelon, Rasburnat, Rasby | *'''Brand names:''' Elitek, Fasturtec, Rasbelon, Rasburnat, Rasby | ||
| Line 23: | Line 24: | ||
[[Category:Uric acid lowering agents]] | [[Category:Uric acid lowering agents]] | ||
| + | [[Category:EMA approved in 2001]] | ||
[[Category:FDA approved in 2002]] | [[Category:FDA approved in 2002]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 12:00, 31 December 2022
General information
Class/mechanism: Recombinant urate-oxidase. Rasburicase catalyzes the enzymatic oxidation of poorly soluble uric acid into allantoin, an inactive and more soluble metabolite.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Rasburicase (Elitek) package insert[1]
History of changes in FDA indication
- 7/12/2002: FDA approved "for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid."[1]
History of changes in EMA indication
- 2/23/2001: Initial authorization as Fasturtec
Also known as
- Brand names: Elitek, Fasturtec, Rasbelon, Rasburnat, Rasby